Use of HCV NS3/4A Protease Inhibitors as Therapeutics for COVID-19
The SARS-CoV-2 virus continues to cause major issues around the globe. Thus, effective therapeutics are critically needed to help better control the virus. Researchers at RPI and collaborating institutions have identified HCV protease inhibitor drugs that may be viable SARS-CoV-2 antivirals. These researchers have used the 3D structure of the SARS-CoV-2 protease to evaluate the potential for 12 FDA-approved HCV drugs to inhibit the SARS-CoV-2 protease.